{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:35:08Z","timestamp":1765370108253},"reference-count":38,"publisher":"American Society of Consultant Pharmacists","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["sr care pharm"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:p><jats:bold>Background<\/jats:bold> Osteoporosis is a common bone disease affecting more than 200 million people worldwide. Commonly prescribed medications have the potential to contribute to bone loss and fracture risk. Providers may be unaware of effects of other commonly used medication classes,\n which can lead to inadequate prevention or a lack of screening.  <jats:bold>Objective<\/jats:bold> To describe a case of drug-induced bone density loss, characterized by long-term use of proton pump inhibitors (PPIs) in a postmenopausal woman; to describe the pharmacist\u2019s role in encouraging\n patient self-advocacy.  <jats:bold>Setting<\/jats:bold> A rural and medically underserved area in eastern Washington State.  <jats:bold>Practice Description<\/jats:bold> This patient case was part of a grant-funded project to identify and intervene with complex and high-risk patients from local rural\n and underserved populations.  <jats:bold>Practice Innovation<\/jats:bold> A pharmacist met with a 61-year-old female patient to complete a comprehensive medication review and subsequently identified a risk of osteoporosis secondary to long-term PPI and hormone replacement therapy use. Empowered\n by the knowledge of risk of development of low bone density, the patient approached her provider twice with a request for bone density measurement.  <jats:bold>Results<\/jats:bold> Despite initial hesitancy from her physician, the patient advocated for herself with concerns about developing osteoporosis.\n Following obtaining a dual energy X-ray absorptiometry scan, the patient received a diagnosis of osteoporosis.  <jats:bold>Discussion<\/jats:bold> Education from the pharmacist prompted the patient to advocate for osteoporosis screening and ultimately led to a diagnosis.  <jats:bold>Conclusion<\/jats:bold>\n Pharmacists play a critical role in identifying medication-induced conditions in patients with complex medications and multiple chronic disease states.<\/jats:p>","DOI":"10.4140\/tcp.n.2022.612","type":"journal-article","created":{"date-parts":[[2022,12,4]],"date-time":"2022-12-04T16:09:15Z","timestamp":1670170155000},"page":"612-622","source":"Crossref","is-referenced-by-count":4,"title":["The Role of the Pharmacist in Patient Self-Advocacy for Osteoporosis Screening"],"prefix":"10.4140","volume":"37","author":[{"given":"Kimberly C.","family":"McKeirnan","sequence":"first","affiliation":[{"name":"1 Washington State University College of Pharmacy and Pharmaceutical Sciences, Pharmacotherapy Department, Spokane, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candace B.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2 Medication Review, Inc., Spokane, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa J.","family":"Powell","sequence":"additional","affiliation":[{"name":"1 Washington State University College of Pharmacy and Pharmaceutical Sciences, Pharmacotherapy Department, Spokane, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubi","family":"Gilbert","sequence":"additional","affiliation":[{"name":"3 Aging and Long-Term Care of Eastern Washington, Spokane, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan R.","family":"Undeberg","sequence":"additional","affiliation":[{"name":"1 Washington State University College of Pharmacy and Pharmaceutical Sciences, Pharmacotherapy Department, Spokane, Washington."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","reference":[{"key":"ref1","year":"2004"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2005.11.024","article-title":"Osteoporosis: a still increasing prevalence.","volume":"38","year":"2006","journal-title":"Bone."},{"issue":"2","key":"ref3","first-page":"187","article-title":"Osteoporosis and fracture risk in older people.","volume":"14","year":"2014","journal-title":"Clin Med (Lond)."},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13018-019-1226-6","article-title":"Mortality after osteoporotic hip fracture: incidence, trends, and associated factors.","volume":"14","year":"2019","journal-title":"J Orthop Surg Res."},{"issue":"7","key":"ref5","first-page":"2045","article-title":"et al.","volume":"26","year":"2015","journal-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis"},{"issue":"10","key":"ref6","volume":"98","year":"2018","journal-title":"Am Fam Physician."},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1759720X14546350","article-title":"Medication-induced osteoporosis: screening and treatment strategies.","volume":"6","year":"2014","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"ref8","first-page":"1","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20142020 update.","volume":"1","year":"2020","journal-title":"Endocr Pract."},{"key":"ref9","article-title":"Proton Pump Inhibitors (PPI) [Updated August 1, 2021].","volume-title":"In: StatPearls [Internet].","year":"2022"},{"key":"ref10","first-page":"2042098618809927","article-title":"The risks of long-term use of proton pump inhibitors: a critical review.","volume":"10","year":"2018","journal-title":"Ther Adv Drug Saf."},{"key":"ref11"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00198-018-4788-y","article-title":"Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.","volume":"30","year":"2019","journal-title":"Osteoporos Int."},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.","volume":"117","year":"2022","journal-title":"Am J Gastroenterol."},{"issue":"1","key":"ref14","first-page":"10","article-title":"Respecting the patient\u2019s choice: a case of possible drug-induced parkinsonism.","volume":"10","year":"2022","journal-title":"Pharmacy (Basel)."},{"key":"ref15","article-title":"A case of pharmacist-led care team interventions to maximize rural patient quality of life.","year":"2021","journal-title":"Exploratory Research in Clinical and Social Pharmacy."},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"E279","DOI":"10.1016\/j.japh.2021.01.005","article-title":"Using the Patient Activation Measure during a pharmacist-led rural patient home visit pilot project.","volume":"61","year":"2021","journal-title":"J Am Pharm Assoc."},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4140\/TCP.n.2020.113","volume":"35","year":"2020","journal-title":"Sr Care Pharm."},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4140\/TCP.n.2020.75","volume":"35","year":"2020","journal-title":"Sr Care Pharm."},{"issue":"4","key":"ref19","first-page":"1","article-title":"Implementing pharmacist-led patient home visits.","volume":"66","year":"2019","journal-title":"Journal of Contemporary Pharmacy Practice."},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.japh.2018.10.019","article-title":"Rural patient perceptions of pharmacist-provided chronic condition management in a state with provider status.","volume":"59","year":"2019","journal-title":"J Am Pharm Assoc (2003)."},{"key":"ref21","article-title":"Pharmacy Quality Alliance."},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jmwh.12954","volume":"64","year":"2019","journal-title":"J Midwifery Womens Health."},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/21556660.2019.1579728","article-title":"Challenges in osteoporosis awareness and management: results from a survey of US postmenopausal women.","volume":"8","year":"2019","journal-title":"J Drug Assess."},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/GME.0000000000001831","volume":"28","journal-title":"Menopause."},{"issue":"3","key":"ref25","first-page":"389","article-title":"Osteoporosis screening and risk management.","volume":"2","year":"2007","journal-title":"Clin Interv Aging."},{"key":"ref26","volume-title":"Dietary Reference Intakes for Calcium and Vitamin D.","year":"2011"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jgs.12631","article-title":"Recommendations abstracted from the American Geriatrics Society Consensus Statement on Vitamin D for Prevention of Falls and Their Consequences.","volume":"62","year":"2014","journal-title":"J Am Geriatr Soc."},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11926-008-0020-y","article-title":"Calcium and vitamin D: skeletal and extraskeletal health.","volume":"10","year":"2008","journal-title":"Curr Rheumatol Rep."},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2004-2364","article-title":"Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy.","volume":"90","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"ref30","first-page":"350356","article-title":"Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.","volume":"130","year":"1994","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/02841860903575273","article-title":"Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.","volume":"49","year":"2010","journal-title":"Acta Oncol."},{"key":"ref32","first-page":"i5014","article-title":"Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.","volume":"354","year":"2016","journal-title":"BMJ."},{"issue":"9","key":"ref33","doi-asserted-by":"crossref","first-page":"e1156","DOI":"10.4088\/JCP.12f08054","article-title":"Breast cancer and antidepressant use.","volume":"73","year":"2012","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10549-012-2330-z","article-title":"Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.","volume":"137","year":"2013","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-016-3765-4","article-title":"Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions.","volume":"156","year":"2016","journal-title":"Breast Cancer Res Treat."},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"ITC97","DOI":"10.7326\/AITC202107200","volume":"174","year":"2021","journal-title":"Ann Intern Med."},{"issue":"4 Pt 1","key":"ref37","first-page":"1005","article-title":"Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers.","volume":"39","year":"2004","journal-title":"Health Serv Res."},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1090198115579415","article-title":"Personalized strategies to activate and empower patients in health care and reduce health disparities.","volume":"43","year":"2016","journal-title":"Health Educ Behav."}],"container-title":["The Senior Care Pharmacist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ascp\/tscp\/2022\/00000037\/00000012\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T15:52:13Z","timestamp":1670428333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.4140\/TCP.n.2022.612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"alternative-id":["2639-9636(20221201)37:12L.612;1-"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2022.612","relation":{},"ISSN":["2639-9636"],"issn-type":[{"value":"2639-9636","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}